Table of Contents

company-logo

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte Dividend Announcement

• Humacyte does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Humacyte dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Humacyte Dividend History

Humacyte Dividend Yield

Humacyte current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Humacyte stock? Use our calculator to estimate your expected dividend yield:

Humacyte Financial Ratios

P/E ratio-5798.93
PEG ratio508.26
P/B ratio-10344.08
ROE869.16%
Payout ratio0.00%
Current ratio1.10
Quick ratio1.10
Cash Ratio0.98

Humacyte Dividend FAQ

Does Humacyte stock pay dividends?
Humacyte does not currently pay dividends to its shareholders.
Has Humacyte ever paid a dividend?
No, Humacyte has no a history of paying dividends to its shareholders. Humacyte is not known for its dividend payments.
Why doesn't Humacyte pay dividends?
There are several potential reasons why Humacyte would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Humacyte ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Humacyte has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Humacyte a dividend aristocrat?
Humacyte is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Humacyte a dividend king?
Humacyte is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Humacyte a dividend stock?
No, Humacyte is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Humacyte stocks?
To buy Humacyte you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Humacyte stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.